Labviva, a Boston-based digital procurement platform purpose-built for the life sciences industry, has announced a $20 million Series A funding round aimed at accelerating the global rollout of its AI-integrated software. The fresh capital, disclosed on March 28, 2023, is expected to help the American software developer expand its reach among pharmaceutical companies, academic research institutions, and scientific suppliers while introducing new complementary product offerings designed to improve organizational purchasing transparency and compliance.
The funding round is led by Biospring Partners, a healthcare and life sciences-focused growth equity firm, with additional participation from B Capital Group, Senator Investment Group, and Glasswing Ventures—all existing backers. The latest infusion brings Labviva’s total capital raised to $30 million since its founding, underscoring growing investor confidence in the company’s vision to modernize and streamline procurement workflows in one of the world’s most research-intensive sectors.
How is Labviva planning to use its latest $20 million Series A funding to scale globally?
According to Labviva, the $20 million raised will be used to accelerate deployment of its software-as-a-service (SaaS) marketplace for both pharmaceutical enterprises and academic research institutions across international markets. The funds will also support the development of new product lines designed to complement its core platform, which serves as a centralized digital procurement hub connecting buyers with scientific suppliers.
Co-founder and CEO Siamak Baharloo emphasizes that Labviva’s goal is to empower scientists and procurement professionals with greater visibility, compliance, and control over organizational spending. The platform is engineered to aggregate hundreds of supplier catalogs into a unified digital interface that allows seamless product discovery, search, and purchasing.
“We are enabling research organizations and pharmaceutical buyers to take control of their spend while maintaining strict adherence to procurement protocols,” Baharloo stated. “By integrating with enterprise procurement systems, we bring researchers and purchasing departments into a unified marketplace that respects scientific context and operational requirements.”
What makes Labviva’s AI-powered platform different from conventional procurement software in life sciences?
Labviva is not a generic e-procurement solution repurposed for scientific buyers. It is designed by scientists, for scientists—an approach that has won it credibility with research-intensive institutions and suppliers alike. Its platform leverages artificial intelligence to parse complex metadata, product descriptions, and contextual research needs, aligning procurement activities with scientific intent.
The platform integrates directly with commonly used procurement systems such as JAGGAER, SAP Ariba, Oracle Procurement Cloud, Coupa, and Microsoft Dynamics 365. This embedded integration allows purchasing departments to access Labviva’s enriched supplier marketplace within their existing workflows, eliminating the need to toggle between multiple systems or rely on outdated catalog interfaces.
“Labviva is the only procurement solution built by scientists with research outcomes considered at every step,” said Jennifer Lum, Co-Founder and Managing Partner at Biospring Partners, the round’s lead investor. “It has the potential to redefine spend culture in life sciences, by enabling real-time insight into procurement behaviors—before decisions are made, not after.”
What industry problems is Labviva trying to solve in the research and pharma procurement space?
Procurement in the life sciences industry has traditionally been fragmented and inefficient, often relying on siloed systems and outdated supplier relationships. Scientific organizations face the dual challenge of adhering to strict compliance frameworks while also ensuring that researchers have timely access to highly specialized reagents, chemicals, instrumentation, and consumables.
In this landscape, Labviva’s marketplace introduces transparency, data-enriched discovery, and organizational-level control that is often lacking in traditional setups. By consolidating multiple supplier catalogs and aligning product recommendations with scientific context, the platform aims to remove friction and error from the procurement cycle.
Moreover, Labviva’s AI models learn from search behaviors and purchase histories to surface relevant products faster—helping reduce order duplication, non-compliant purchases, and budget overruns. These features resonate particularly with larger pharma companies and university laboratories that must enforce strict procurement policies while maintaining scientific agility.
What is the market opportunity and competitive positioning of Labviva in 2023?
The digital transformation of life sciences procurement is still in its early stages. Analysts estimate that global R&D procurement spend exceeds $150 billion annually, yet much of this is still managed through legacy systems or manual workflows. Labviva positions itself at the intersection of enterprise procurement and scientific enablement, addressing a market gap that few legacy ERP vendors have been able to serve effectively.
Backers like B Capital Group and Senator Investment Group believe the platform’s science-first architecture offers a durable competitive advantage. Its ability to contextualize product data, streamline procurement approvals, and integrate deeply with enterprise resource planning (ERP) software provides utility that off-the-shelf SaaS marketplaces cannot replicate in regulated scientific environments.
Biospring’s Lum reinforces this thesis by noting that Labviva’s market opportunity lies not just in process automation, but in reshaping how scientific organizations think about procurement culture. “They’re not just digitizing purchase orders—they’re helping redefine how scientific intent, data transparency, and operational control work together,” Lum added.
How does Labviva’s funding reflect broader digital transformation trends in life sciences?
Labviva’s Series A round comes amid a broader wave of investment into digital tools that improve operational efficiency in life sciences. From cloud-based laboratory management systems to AI-driven drug discovery platforms, investors are increasingly targeting startups that help pharmaceutical companies and research institutions modernize their infrastructure.
The COVID-19 pandemic highlighted how fragile global research supply chains could be. In its wake, scientific organizations are increasingly looking to platforms like Labviva to build resilient, transparent procurement ecosystems that minimize dependency risks while supporting agile experimentation. With Labviva’s data-rich marketplace, stakeholders gain forward-looking insights into sourcing behaviors and can apply procurement strategies more proactively.
Labviva’s growth also reflects a shift in enterprise expectations. Where procurement was once viewed as a back-office function, it is now being reimagined as a strategic lever tied directly to scientific outcomes and operational scale. That reorientation—placing procurement closer to the heart of R&D—aligns closely with Labviva’s founding vision.
What’s next for Labviva as it looks to expand internationally and deepen product offerings?
With $20 million in fresh capital and momentum from a growing customer base, Labviva is preparing to broaden its global footprint. While the company is already active across multiple geographies, the new funding is expected to accelerate platform deployments in Europe, Asia-Pacific, and other research-intensive markets.
The American SaaS developer also plans to enhance its product suite, building complementary tools that support procurement analytics, supplier relationship management, and workflow customization for different buyer archetypes. Though specific product roadmaps are not yet public, institutional customers can expect continued innovation focused on scientific contextualization, regulatory compliance, and enterprise usability.
As the platform scales, the long-term challenge for Labviva will be maintaining the scientific depth and data integrity that differentiate it from general-purpose e-commerce marketplaces. That balance—between operational scale and scientific specificity—will likely define its next phase of growth.
Can Labviva define the future of scientific procurement with its AI-first strategy?
Labviva’s $20 million Series A is more than a funding milestone—it’s a validation of its mission to modernize how research organizations source the materials that power discovery. At a time when life sciences companies are being pressed to do more with less, while maintaining compliance and accelerating innovation, platforms like Labviva offer a rare combination of scalability and scientific rigor.
With support from domain-focused investors and a leadership team embedded in both procurement operations and research realities, Labviva is emerging as a serious contender to define a new category in scientific purchasing. Whether the American procurement software developer can sustain this momentum will depend on its ability to scale globally while preserving the scientific fidelity that underpins its offering.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
